Event info
Date:31 May
Time:9:00 - 17:00
Venue:London, United Kingdom
Contact person
Nicole Mastrell

Nicole Mastrell

Event Manager & PA to CEO


+45 6141 8634

Formulating the Future: Accelerating Oral Drug Development and Manufacturing

Oral solid dosage forms remain a preferred option for many pharmaceutical drug developers. However, their successful development and manufacture still presents several unique challenges and opportunities. Join this upcoming workshop to discover how you could accelerate progression to the clinic and on to market success.

Date: Tuesday, May 31, 2022 – 9:00-17:00 BST
Location: Royal Society of Chemistry, Burlington House, Piccadilly, London W1J 0BA, United Kingdom







Session Title: Physiologically based Pharmacokinetic Modelling to Support Drug Development

Jan Neelissen, Ph.D., Associate Director, Science & Technology, Catalent

Dr. Jan Neelissen, Associate Director of DMPK Advisory Services, has over 25 years of pharmaceutical industry experience in the field of DMPK. In his current role, he advises drug innovators in developing new therapeutics and designing tailored formulation, delivery and manufacturing solutions. Prior to joining Catalent in 2017, Dr. Neelissen spent 17 years at AstraZeneca where he held various leadership positions including Associate Director in vitro DMPK and Associate Director Modelling and Simulation. Dr. Neelissen is a biologist by training and holds a doctorate in Pharmaceutical Sciences from Leiden University, Leiden, Netherlands.



Session Title: Small-Molecule Manufacturing Options for Expedited Programs

Stephen Tindal, Associate Director, Science & Technology, Catalent

Stephen Tindal is Director of Science and Technology at Catalent, where he plays an important role within the company’s research and development team by providing advice to clients in Europe and Asia-Pacific on the early phase drug development and delivery technologies to progress their small molecule programs. His work is largely focused on preclinical to phase 1 development and is based on the assessment of preclinical data to help define any challenges to dosage form development. Tindal has more than 30 years’ experience at Catalent where he has held roles of increasing responsibility, and has demonstrated expertise in root cause investigation, technology innovation and in supporting business development. He holds a bachelor’s in Chemistry and Analytical Science from Loughborough University, Loughborough, U.K.